vs
Medpace Holdings, Inc.（MEDP）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
RANGE RESOURCES CORP的季度营收约是Medpace Holdings, Inc.的1.1倍（$786.9M vs $708.5M），RANGE RESOURCES CORP净利率更高（22.8% vs 19.1%，领先3.7%），Medpace Holdings, Inc.同比增速更快（32.0% vs 18.0%），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 14.6%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
MEDP vs RRC — 直观对比
营收规模更大
RRC
是对方的1.1倍
$708.5M
营收增速更快
MEDP
高出14.1%
18.0%
净利率更高
RRC
高出3.7%
19.1%
两年增速更快
MEDP
近两年复合增速
14.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $786.9M |
| 净利润 | $135.1M | $179.1M |
| 毛利率 | — | 94.5% |
| 营业利润率 | 21.6% | — |
| 净利率 | 19.1% | 22.8% |
| 营收同比 | 32.0% | 18.0% |
| 净利润同比 | 15.5% | 88.8% |
| 每股收益（稀释后） | $4.65 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRRC
| Q4 25 | $708.5M | $786.9M | ||
| Q3 25 | $659.9M | $655.3M | ||
| Q2 25 | $603.3M | $699.6M | ||
| Q1 25 | $558.6M | $846.3M | ||
| Q4 24 | $536.6M | $667.0M | ||
| Q3 24 | $533.3M | $567.9M | ||
| Q2 24 | $528.1M | $513.2M | ||
| Q1 24 | $511.0M | $598.8M |
净利润MEDPRRC
| Q4 25 | $135.1M | $179.1M | ||
| Q3 25 | $111.1M | $144.3M | ||
| Q2 25 | $90.3M | $237.6M | ||
| Q1 25 | $114.6M | $97.1M | ||
| Q4 24 | $117.0M | $94.8M | ||
| Q3 24 | $96.4M | $50.7M | ||
| Q2 24 | $88.4M | $28.7M | ||
| Q1 24 | $102.6M | $92.1M |
毛利率MEDPRRC
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
营业利润率MEDPRRC
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 19.9% | — | ||
| Q1 24 | 20.4% | — |
净利率MEDPRRC
| Q4 25 | 19.1% | 22.8% | ||
| Q3 25 | 16.8% | 22.0% | ||
| Q2 25 | 15.0% | 34.0% | ||
| Q1 25 | 20.5% | 11.5% | ||
| Q4 24 | 21.8% | 14.2% | ||
| Q3 24 | 18.1% | 8.9% | ||
| Q2 24 | 16.7% | 5.6% | ||
| Q1 24 | 20.1% | 15.4% |
每股收益（稀释后）MEDPRRC
| Q4 25 | $4.65 | $0.75 | ||
| Q3 25 | $3.86 | $0.60 | ||
| Q2 25 | $3.10 | $0.99 | ||
| Q1 25 | $3.67 | $0.40 | ||
| Q4 24 | $3.67 | $0.38 | ||
| Q3 24 | $3.01 | $0.21 | ||
| Q2 24 | $2.75 | $0.12 | ||
| Q1 24 | $3.20 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $459.1M | $4.3B |
| 总资产 | $2.0B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资MEDPRRC
| Q4 25 | $497.0M | $204.0K | ||
| Q3 25 | $285.4M | $175.0K | ||
| Q2 25 | $46.3M | $134.0K | ||
| Q1 25 | $441.4M | $344.6M | ||
| Q4 24 | $669.4M | $304.5M | ||
| Q3 24 | $656.9M | $277.4M | ||
| Q2 24 | $510.9M | $251.1M | ||
| Q1 24 | $407.0M | $343.1M |
总债务MEDPRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益MEDPRRC
| Q4 25 | $459.1M | $4.3B | ||
| Q3 25 | $293.6M | $4.2B | ||
| Q2 25 | $172.4M | $4.1B | ||
| Q1 25 | $593.6M | $3.9B | ||
| Q4 24 | $825.5M | $3.9B | ||
| Q3 24 | $881.4M | $3.9B | ||
| Q2 24 | $763.6M | $3.9B | ||
| Q1 24 | $671.5M | $3.8B |
总资产MEDPRRC
| Q4 25 | $2.0B | $7.4B | ||
| Q3 25 | $1.8B | $7.2B | ||
| Q2 25 | $1.6B | $7.1B | ||
| Q1 25 | $1.9B | $7.4B | ||
| Q4 24 | $2.1B | $7.3B | ||
| Q3 24 | $2.1B | $7.2B | ||
| Q2 24 | $1.9B | $7.3B | ||
| Q1 24 | $1.8B | $7.4B |
负债/权益比MEDPRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | 1.44× |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPRRC
| Q4 25 | $192.7M | $257.5M | ||
| Q3 25 | $246.2M | $247.5M | ||
| Q2 25 | $148.5M | $336.2M | ||
| Q1 25 | $125.8M | $330.1M | ||
| Q4 24 | $190.7M | $217.9M | ||
| Q3 24 | $149.1M | $245.9M | ||
| Q2 24 | $116.4M | $148.8M | ||
| Q1 24 | $152.7M | $331.9M |
自由现金流MEDPRRC
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | — |
自由现金流率MEDPRRC
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | — |
资本支出强度MEDPRRC
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.1% | — |
现金转化率MEDPRRC
| Q4 25 | 1.43× | 1.44× | ||
| Q3 25 | 2.22× | 1.72× | ||
| Q2 25 | 1.65× | 1.42× | ||
| Q1 25 | 1.10× | 3.40× | ||
| Q4 24 | 1.63× | 2.30× | ||
| Q3 24 | 1.55× | 4.85× | ||
| Q2 24 | 1.32× | 5.18× | ||
| Q1 24 | 1.49× | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
